APA (7th ed.) Citation

Kaeuferle, T., Zwermann, M., Stoll, N., Ferrada-Ernst, P., Jablonowski, L., Zeidler, R., . . . Feuchtinger, T. (2025, March). All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone. Experimental Hematology & Oncology.

Chicago Style (17th ed.) Citation

Kaeuferle, Theresa, et al. "All-in-one CRISPR/Cas-engineered Glucocorticoid-receptor Knock-out EBV-gp350-CAR Knock-in T Cells Are Potent and Resistant to Dexamethasone." Experimental Hematology & Oncology Mar. 2025.

MLA (9th ed.) Citation

Kaeuferle, Theresa, et al. "All-in-one CRISPR/Cas-engineered Glucocorticoid-receptor Knock-out EBV-gp350-CAR Knock-in T Cells Are Potent and Resistant to Dexamethasone." Experimental Hematology & Oncology, Mar. 2025.